
Organovo Holdings ONVO
Quarterly report 2025-Q4
added 02-11-2026
Organovo Holdings General and Administrative Expenses 2011-2026 | ONVO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.73 M | 9.7 M | 9.22 M | 15.7 M | 17.2 M | 15.1 M | 20.9 M | 22.3 M | 22.1 M | 17.9 M | 13.1 M | 2.79 M | 7.08 M | 120 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.3 M | 120 K | 12.9 M |
Quarterly General and Administrative Expenses Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 M | 1.74 M | 1.95 M | - | 1.71 M | 1.65 M | 2.02 M | - | 2.25 M | 2.78 M | 2.6 M | - | 2.3 M | 2.2 M | 2.22 M | - | 2.57 M | 7.38 M | 4.81 M | - | 2.09 M | 2.09 M | 8.92 M | 2.79 M | 5.37 M | 5.37 M | 6.35 M | 3.32 M | 3.39 M | 3.39 M | 3.64 M | - | 4.86 M | 5.74 M | 5.86 M | - | 5.55 M | 16.5 M | 11 M | - | 6.21 M | 17.7 M | 11.5 M | - | 3.88 M | 13.4 M | 9.47 M | - | 2.38 M | 8.74 M | 6.36 M | 2.79 M | 2.14 M | 6.18 M | 4.04 M | 902 K | 3.91 K | 2.62 K | 6.53 K | 37.2 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.7 M | 2.62 K | 4.63 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 117.74 | -1.68 % | $ 35.8 B | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 19.95 | -2.97 % | $ 211 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 22.11 | 25.81 % | $ 1.18 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.42 | - | $ 1.89 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.49 | -0.53 % | $ 680 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 179.73 | -0.51 % | $ 8.91 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Danaher Corporation
DHR
|
8.24 B | $ 194.65 | -1.74 % | $ 139 B | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.93 | -12.09 % | $ 8.54 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.09 B | $ 130.0 | -1.71 % | $ 20.7 B | ||
|
Medpace Holdings
MEDP
|
198 M | $ 521.19 | 0.51 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 16.04 | -0.8 % | $ 485 M | ||
|
NeoGenomics
NEO
|
273 M | $ 8.39 | -3.34 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.18 | -2.55 % | $ 1.99 B | ||
|
Guardant Health
GH
|
211 M | $ 85.27 | 0.48 % | $ 10.7 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 2.84 | -3.07 % | $ 92.2 K | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.19 | 4.03 % | $ 5.03 M | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 29.07 | - | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 115.89 | -0.52 % | $ 9.56 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 267.91 | 0.38 % | $ 22.3 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Celcuity
CELC
|
27.2 M | $ 122.94 | -0.43 % | $ 5.75 B | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 6.78 | -1.74 % | $ 283 M | ||
|
Myriad Genetics
MYGN
|
257 M | $ 5.16 | -0.67 % | $ 478 M | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 83.51 | -0.51 % | $ 5.64 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 52.62 | 0.1 % | $ 2.67 B | ||
|
Neuronetics
STIM
|
31.5 M | $ 1.36 | -2.52 % | $ 89.7 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 193.55 | 1.16 % | $ 21.5 B | ||
|
ENDRA Life Sciences
NDRA
|
3.72 M | $ 5.2 | 1.17 % | $ 4.09 M | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 522.74 | -1.65 % | $ 197 B | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.81 | -0.17 % | $ 399 M |